• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

"Up the Price by How Much?"

Poll

Turing Pharmaceutical's CEO has backed down on the 4000% price hike for Daraprim, but is the damage done? Take our poll.

You’ve read about Turing Pharmaceuticals’ recent attempt to increase the cost of Daraprim by about 4000%.  

Do you think this move is:

A. Legitimate: funds will help subsidize new drug development
B. Motivated purely by financial gain and a harbinger of more to come
C. Not new: others have done it
D. A swan song: public and political pressure will stop this from becoming a trend
E. A priority issue for 2016 presidential candidates
F. Other
Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
Mazdutide Demonstrates Superior Glycemic Control and Weight Loss vs Semaglutide in Head-to-Head Trial / image credit eking University People’s Hospital

Mazdutide Demonstrates Superior Glycemic Control and Weight Loss vs Semaglutide in Head-to-Head Trial

Grace Halsey
October 28th 2025
Article

The phase 3 DREAMS-3 trial is the fist phase 3 head-to-head comparison of a GLP-1/glucagon dual receptor agonist against semaglutide in diabetes treatment.

Weekly Dose Podcast: Arrhythmias as Early Risk Markers, Flu Vaccine Safety, Salt Substitute Use, Preconception CT Risks, and Global Diabetes Care Gaps

Weekly Dose Podcast: Arrhythmias as Early Risk Markers, Flu Vaccine Safety, Salt Substitute Use, Preconception CT Risks, and Global Diabetes Care Gaps

Sydney Jennings
October 2nd 2025
Podcast

Today's episode highlights arrhythmias as CVD risk markers, influenza vaccine safety, salt substitute use, preconception CT scan risks, and global diabetes care gaps.

AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial

AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial

Grace Halsey
October 27th 2025
Article

After 1 year of coaching by the AI app or a DPP-associated coach, reductions in weight and HbA1c and increases in physical activity were equal, an outcome with great promise for scalability.

Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes

Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes

Sydney Jennings
September 24th 2025
Podcast

Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.

FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause

FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause

Sydney Jennings
October 24th 2025
Article

The novel once-daily nonhormonal therapy offers a new option to offer women who prefer not to take HRT or for whom it is contraindicated.

Menopause: A Constellation of Syndromes / image credit ©Cienpies Design/stock.adobe.com

Menopause: A Constellation of Syndromes Across 13 Body Systems

October 24th 2025
Article

Our short slide show outlines interrelated syndromes of menopause across 13 body systems, implicating therapeutic targets and approaches for clinical practice.

© 2025 MJH Life Sciences

All rights reserved.